Smith–Lemli–Opitz syndrome disease incidence has been studied, primarily in Europe and Canada. Diagnoses have been confirmed by molecular and biochemical methods. Most figures range from 1/60 00011, 12 to 1/20 000.
The information presented on this website is not intended as specific medical advice and is not a substitute for professional treatment or diagnosis. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
